CytRx Corporation

Commission releases biopharmaceutical company from conflict of interest inquiry

Published in Lab Business Week, July 17th, 2005

CytRx Corporation (CYTR), a biopharmaceutical company developing human therapeutics in the area of small molecules and ribonucleic acid interference (RNAi), announced it has received notification from the Massachusetts State Ethics Commission that the company has been released from a preliminary conflict of interest inquiry without a finding of wrongdoing on the part of the company.

CytRx was notified in February 2004 that the Massachusetts Commission had initiated a preliminary inquiry into whether the company's previous retention of a consultant who introduced the company to the University of Massachusetts Medical School (UMMS) constituted an improper conflict of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-07-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry